SENTARA COMMUNITY PLAN (MEDICAID)

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

Gastrointestinal (GI) Antibiotics

DRUG REQUESTED: (Check box below that applies)

| PREFERRED Drugs | | | | | | | | | |
|---|------------------------------------|---|---|--|--|--|--|--|--|
| | metronidazole tab (250mg/500mg) | □ vancomycin cap | vancomycin for reconstitution oral soln kit (generic Firvanq[™] soln) | | | | | | |
| Non-Preferred Drugs (Require a Prior Authorization) | | | | | | | | | |
| | Aemcolo TM | ☐ Alinia [®] ☐ nitazoxanide (generic Alinia [®]) | □ Dificid [®] | | | | | | |
| | Firvanq [™] soln | □ Flagyl® cap/tab/ER | □ Likmez [™] | | | | | | |
| | metronidazole 125mg | □ metronidazole cap | □ neomycin | | | | | | |
| | paromomycin | □ Solosec® | □ Tindamax [®] | | | | | | |
| | tinidazole | □ Vancocin® | □ Vowst [™] (refer to Vowst PA form) | | | | | | |
| | Xifaxan [®] | | | | | | | | |
| M | EMBER & PRESCRIB | ER INFORMATION: Authorizatio | n may be delayed if incomplete. | | | | | | |
| Mei | nber Name: | | | | | | | | |
| Mei | nber Sentara #: | Date of Birth: | | | | | | | |
| Pres | scriber Name: | | | | | | | | |
| Pres | scriber Signature: | Date: | | | | | | | |
| Offi | ce Contact Name: | | | | | | | | |
| Pho | ne Number: | Fax Nui | nber: | | | | | | |
| NIDI | - μ. | | | | | | | | |

(Continued on next page)

| DRUG INFORMATION: Authorization may be delayed if incomplete. | | | | | | | |
|--|---|-------------|----------|--------|---------|--|--|
| Drug Nan | ne/Form/Strength: | | | | | | |
| Dosing Sc | hedule: Length of Therapy | y: | | | | | |
| | | | | | | | |
| | | | | | | | |
| support ea | PRUG INFORMATION: Authorization may be delayed if incomplete. Prug Name/Form/Strength: | | | | | | |
| | | ing or inte | rferes v | with t | olanned | | |
| · | = | _ | | _ | | | |
| * | following: Azithromycin (generic Zithromax), Ciprofloxacin (generic | Cipro), Le | voflox | acin (| | | |
| 2. <u>Ali</u> | nia® tablets – Quantity Limit: 6 tabs per rolling 30 days (Length of | Authorizat | ion: da | ate of | service | | |
| | | | | | | | |
| * | Diagnosis of diarrhea caused by Cryptosporidium parvum or Giardia l | amblia, 🗖 | Yes | | No | | |
| * | Patient has had a trial on metronidazole or oral vancomycin? | | Yes | | No | | |
| 3. Ali | nia® suspension (Length of Authorization: date of service) | | | | | | |
| | · · · · · | | Yes | | No | | |
| | | amblia 🗖 | Yes | | No | | |
| | Patient has had a trial on metronidazole or oral vancomycin? | | Yes | | No | | |
| * | | | | | | | |
| | • | | Yes | | No | | |
| | ; | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | · | | Yes | | No | | |
| | | _ | * 7 | _ | | | |
| | Patient diagnosed with hepatic coma? | | | _ | No | | |
| | Patient diagnosed with surgical (perioperative) prophylaxis? | | Yes | | No | | |
| * | Patient diagnosed with hepatic encephalopathy? | | Yes | | No | | |
| · | | | | | | | |
| * | Patient is $\geq 12 \text{ years}$ old? | | | | No | | |
| * | Diagnosed with travelers' diarrhea caused by noninvasive strains of E | . coli? | Yes | | No | | |

(Continued on next page)

PA Gastrointestinal Antibiotics (Medicaid)

(Continued from previous page)

| 7. Xifaxan [®] 550mg | | | | | | |
|---|-------|--------|----|----|--|--|
| ❖ Patient is \ge 18 years old? | | Yes | | No | | |
| Diagnosed with: (check applicable diagnosis below): | | | | | | |
| ☐ Irritable bowel syndrome with diarrhea (IBS-D)? | | Yes | | No | | |
| ☐ Irritable bowel syndrome with diarrhea (IBS-D) and had chronic syn | npton | | | | | |
| months? | | Yes | | No | | |
| ☐ <u>Initial Approval</u> : 550 TID for 14 days | | | | | | |
| ☐ Reauthorization Approval: 42 tablets/14 days, can be retreated up to two times we the same regimen. (Maximum Quantity Limit:126 tablets/365 days) | | | | | | |
| | | Yes | | No | | |
| ☐ Hepatic encephalopathy (Quantity Limit: 2 tablets/day) | | | | | | |
| | | Yes | | No | | |
| ☐ Trial and failure of lactulose 20 to 30g (30 - 45mL) 3 to 4 times | daily | | | | | |
| | | Yes | | No | | |
| | | | | | | |
| MEDICAL NECESSITY: Provide clinical evidence that the PREFERRED of provide adequate benefit. | lrugs | will N | ОТ | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

**Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. **

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.